Friday | 21 November, 2008
Stories about: MPC
- +
Mesoblast's long-term protection 16/07/2008 12:41:56
Mesoblast awarded extended patent for MPC stem cells - +
The near-term potential of stem cell therapies 08/04/2005 13:31:56
The prospect of therapies based on human stem cells holds great promise for revolutionising the practice of medicine, says Silviu Itescu. - +
Mesoblast lists at a premium 16/12/2004 14:59:09
Trapping and harnessing adult mesenchymal precursor cells (MPCs) - some of the rarest and most valuable cells in the body - is the game of junior biotech Mesoblast (ASX:MSB) - which listed on the ASX today at AUD$0.91, almost double its issue price of $0.50.
Additional Resources
Newsletter Subscription
Australian Life Scientist Member Login
Kingston Technology Launches HyperX T1 Series Memory 2008-11-19 11:00:00+11
Erase your discs with Lite-On SmartErase 2008-11-12 14:00:00+11
Antarctica NZ to Optimise Satellite Communications over the WAN with Expand Networks 2008-11-11 08:22:00+11
Kingston Technology Launches HyperX DDR3 2GHz Triple-Channel Memory in Support of Intel Core i7, X58 Platforms 2008-11-06 16:40:00+11
WD TV™ HD Media Player brings Digital Media Collections to the Big Screen 2008-11-05 11:00:00+11
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector.
